Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CanSino BiologicsCASBF 69 Gross Margin % is 29.09% as of Dec. 2025, which is 39% below its 10-year median of 47.69. GuruFocus rates CASBF with a GF Score™ of 69/100 and a GF Value™ of $8.72 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 943 Drug Manufacturers companies, CanSino Biologics ranks better than 85.9% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
CanSino Biologics had a gross margin of 29.09% for the quarter that ended in Dec. 2025 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
CanSino Biologics Gross Margin % Related Terms
CanSino Biologics Gross Margin % Historical Data
* Premium members only.
The historical data trend for CanSino Biologics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, CanSino Biologics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CanSino Biologics Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CanSino Biologics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where CanSino Biologics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
CanSino Biologics (CASBF) has a Gross Margin % of 29.09% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on CanSino Biologics and its competitors. This is 39% below median its historical median of 47.69. According to the industry distribution chart, CanSino Biologics ranks #133 out of 943 companies in the Drug Manufacturers industry, placing it in the top 14.1%.
Is CanSino Biologics' Gross Margin % too high?
CanSino Biologics' current Gross Margin % of 29.09% is 39% below median its 10-year median of 47.69. The Drug Manufacturers industry median Gross Margin % is 48.54. CanSino Biologics' value of 29.09% is 40.1% below this industry median. Based on the distribution chart, CanSino Biologics ranks #133 out of 943 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, CanSino Biologics has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CanSino Biologics' Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, CanSino Biologics ranks #133 out of 943 companies for Gross Margin %. This places CanSino Biologics in the top 14% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.54. CanSino Biologics' value of 29.09% is 40.1% below this benchmark. While the company's 10-year median is 47.69 vs. the industry median of 48.54, CanSino Biologics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CanSino Biologics's current Gross Margin % of 29.09% is 40.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on CanSino Biologics and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CanSino Biologics's current Gross Margin % is 29.09%, which is 39% below median its own 10-year median of 47.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CanSino Biologics stock overvalued right now?
Based on GuruFocus' analysis, CanSino Biologics (CASBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $8.72, compared to a current price of $2.60 — trading 70.2% below its estimated fair value. The current Gross Margin % is 29.09%, which is 39% below median its 10-year median of 47.69 and 40.1% below the Drug Manufacturers industry median of 48.54. CanSino Biologics' overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For CanSino Biologics (CASBF), the current Gross Margin % is 29.09% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CanSino Biologics (CASBF) Overvalued in 2026?
Based on GuruFocus' analysis, CanSino Biologics stock appears to be undervalued.
The current stock price of $2.60 is trading 70.2% below its estimated GF Value™ of $8.72.
GuruFocus considers CanSino Biologics to be Significantly Undervalued.
Key valuation signals for CASBF:
Gross Margin %: 29.09% (39% below median its 10-year median of 47.69)
GF Value™: $8.72 vs. price of $2.60 (70.2% below fair value)
Industry Position: 40.1% below the Drug Manufacturers median (#133 of 943)
No single metric tells the full story. See the CASBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CanSino Biologics Inc is engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. The company has a broad portfolio of vaccines and vaccine candidates for several disease areas. Its commercial-stage products are Menhycia and Menphecia, iPneucia, Convidecia and Convidecia Air, and XBB.1.5 Variant, and Ad5-EBOV. The company's clinical-stage products include Tetanus Vaccine, DTcP Infant, Tdcp Adolescent and Adult, Recombinant Poliomyelitis Vaccine, PBPV, and Recombinant Zoster Vaccine, among others. Additionally, it has various vaccine candidates in pre-clinical programs, targeting diseases such as influenza, meningitis, pneumonia, and others. Geographically, the company generates maximum revenue from the People's Republic of China.
69GF Score
Get the complete analysis for CASBF
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CASBF has been successfully added to your 
